CLINICAL_TRIALS
trial_result
· 2022-02-23
Clinical Trial Update: A Study of Single Doses of Frespaciguat (MK-5475) on Pulmonary Vascular Resistance (MK-5475-002) [Phase 1]
Summary
A Phase 1 study evaluating single doses of Frespaciguat (MK-5475) on pulmonary vascular resistance in patients with pulmonary arterial hypertension has been com…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merck Sharp & Dohme LLC | Conditions: Pulmonary Arterial Hypertension | Phase 1 | Status: COMPLETED | Results posted: 2022-02-23